Introduction
FFR represents the standard of reference for invasive functional evaluation of the ischemic potential of coronary stenosis and is a valuable tool to guide percutaneous revascularization. [1] [2] [3] An FFR value 0.75 is almost uniformly associated with signs of ischemia, [4] [5] [6] [7] [8] [9] while an FFR >0.80 is usually associated with the absence of ischemia. Based on numerous randomized trials [2] [3] [4] [5] and registries in most subsets of lesions and patients, the threshold value of 0.80 has been widely accepted to guide clinical decision-making. [6] [7] [8] [9] [10] [11] Accordingly, in the latest European guidelines, revascularization in patients with stable ischemic heart disease in a wide range of coronary stenosis severity (50-90%) has been recommended under FFR guidance in the absence of objective demonstration of ischemia at noninvasive functional evaluation (Level I, evidence A). 12 Current US guidelines have recommended the use of FFR to guide revascularization in patients with stable ischemic heart disease when FFR is 0.80 (Level IIa, evidence A). 
Methods

Patient population
From February 1997 to June 2013, we retrospectively considered for inclusion patients presenting at the Cardiovascular Center Aalst (Belgium) with an isolated stenosis and an FFR value within the gray zone of 0.76 to 0.80, irrespective of the angiographic severity and lesion location. To serve as controls, we also considered for inclusion patients presenting with an ecommended under FFR guidance in the absence of objective demonstration of is is isch ch chem em emia ia ia a a at t t no no nonnvasive functional evaluation (Level I, evidence A). 12 Current US guidelines have eco omm mm mmen en ende de ded d d th h he us u u e of FFR to guide revascular ar ari i iza za zation in patients wit th h h st s s able ischemic heart d di dise e ease when F F FFR F FR is s s 0. 0. 0.80 80 80 ( (Le Le Leve ve vel l l II II IIa, ev vide de denc c ce A A). . 13 The be be best tre e eatme me ment str tr trat at teg eg egy y y fo fo for in n nterm m me e ediat te ste e eno no nosis s s wi wi with th h F F FFR FR R i i in the e e na na narrow w w " " "gr ray y y zon n ne e" of of of val al alue e ues s s, t t tha ha hat t t is is is b b bet et etwe e ween en en 0 0 0 7 7 .76 6 6 to to to 0 0 0 8 8 .80 0 0, h h has as as b b bee ee een n n quues es esti ti tion on oned ed ed. T T The he here re refo fo fore re re, we e we a a ana na naly l lyze e zed d d th th the e e lo lo long ng ng-isolated stenosis and an FFR value in the adjacent FFR strata of 0.70 to 0.75 and 0.81 to 0.85.
We excluded patients with multivessel and multiple segment disease, prior CABG, in-stent restenosis, myocardial bridging, and prior heart transplantation.
Coronary angiogram
Coronary angiography was performed by a standard percutaneous radial or femoral approach using a 6 or 7 Fr diagnostic or guiding catheters. After the administration of 200 mg intracoronary isosorbide dinitrate, the angiogram was performed in the projection allowing the best possible visualization of the stenosis and avoiding, as far as possible, foreshortening or overlap of other arterial segments.
Quantitative coronary angiography was performed using one of the following software:
Siemens Simultaneous recording of aortic and distal coronary pressure was performed. FFR was calculated as the ratio of hyperemic mean distal coronary pressure to mean aortic pressure.
Quantitative coronary angiography was performed using one of the followi wi wing ng ng s s sof of oftw tw twar ar are e e:
Siemens Healthcare Axiom Artis VB35D110803 (Siemens Medical Solutions, Siemens AG;
Forc c che he heim im im, , , Ge Ge Germ m man an any), Siemens Healthcare ACO OM M M.P .P .PC 5.01 System (Sie e em m mens Medical Solutions, S S Siem m mens AG) ) or or or G Gen n ne er e al al al E E El le lect ct ctri ri ric c AW AW AW V Vol lum um me e eSha are e e 6E E E ( ( (Ge Ge Gen n nera ra ral l El El Elec ec ectr tr tric c Inc nc c. ., ., F F Fai ai airf rf rfie ield ld ld, OH OH OH, , , US US USA) A) A). All me me measur ur ure em e e e ent ts t we e ere e e ob o ta ta tain i i e e ed b by y y an an an expe pe per rien en nc c ced d te e ech h hn n nic c cian an an u u unawa wa are e e of th th the e e FF FR R R e e esu s sult lt lts s s. D D Dat at ata a a we e were re re s s sav a aved ed ed o o on n n a a a di di diff ff ffer er eren en ent t t pa pa page ge ge o o of f f th th the e e lo lo loca ca cal l l da da data ta taba ba base se se. Th Th The e e co co cont nt ntra ra rast st st f f -fil il ille le led d d ca ca cath th thet et eter er er we e were re re e e eit it ithe he her r r sp sp spon on onta ta tane ne neou o ous s s or or or r r rel el ela a ate te ted d d to to to t t the he he r r rev e evas as ascu c cula la lari ri riza a zati ti tion on on p p pe e erf rf rfor or orme me med 
Metrics and clinical endpoints
Results
During the study period, 17380 FFR measurements were performed ( Figure 1 ). Of all these FFR measurements, we considered 8170 values (47%) corresponding to: 2602 (15%) within the gray zone, 1951 (11%) within the 0.70 to 0.75 strata, and 3617 (21%) within the 0.81 to 0.85 strata. We then excluded 6711 measurements because of the presence of multivessel disease, multiple segment disease, prior CABG, in stent restenosis, myocardial bridging or prior heart transplantation. The remaining 1459 patients with single-segment disease were included in our study.
Among these patients, 1010 (70%) received medical therapy and 449 (30%) underwent revascularization. In the latter group, 344 (77%) patients were treated with PCI and 105 (23%)
Meier curves were compared by the log-rank test and were generated to highlight t t th th the e e cu cu cumu mu mula la lati ti tive ate of MACE and Death or MI in the gray zone patients, and MACE-free survival rate within he me me medi di dica ca cal l l th th therap ap apy y y across the 3 FFR strata. P v val al alue ue ues were considered s s sta ta tatistically significant if 
Clinical and angiographic characteristics
Clinical and angiographic characteristics of the patients within the FFR gray zone according to treatment strategy are summarized in the Table 1 Within the group of patients treated with revascularization, there were differences in terms of % diameter stenosis and reference diameter of the vessel across the 3 FFR strata.
Among the patients undergoing percutaneous revascularization (n=344), 180 (52%) underwent drug-elunting stent implantation (DES) and 164 (48%) bare metal stent (BMS) implantation. The reated with medical therapy presented less angiographically severe coronary sten n nos os oses es es ( ( (as as as uggested by lower % diameter stenosis and higher minimal lumen diameter) and slightly higher FFR R R va va valu lu lues es es. . .
Clinical l l a a a d nd a a an ng ngio io iogr gr grap ap aphi hi hic ch ch char a a a a act teri i ist st stic c cs of f th h he MT MT MT a a and nd nd R R Rev ev ev g gro ro oup up u acc c cor or ordi di ding ng ng t t to F F FFR R R st st stra ra rata t t ar r re e e su su summar riz iz ized e e i i in the su u upple le eme me ment tal al al T T Tab b ble 1 1 1. Wit thi i in t t the he he g gro ro roup up up o o of pa pa pati t t en nts s tr r rea ea eate t t d wi wi wit th th m me e edica a al h h her er erap ap apy on on only l ly, th th ther er ere e e we e were re re d d dif if iffe fe fere re renc nc nces es es i i in n n te te term rm rms s s of of of ma ma male le le g g gen en ende de der r r an an and d d % % % di di diam am amet et eter er er s s ste te teno no nosi si sis s s ac ac acro ro ross ss ss t t the he he 3 In the Rev group, there was no difference in any of the clinical endpoints across the 3 FFR strata after revascularization (supplemental table 3).
with the Rev group up to 5 years (Figure 2 ).
Within the group of patients treated with medical therapy only, a progressive significant decr rea ea ease se se i i in n n MA M M CE CE CE rate, and a significant increa ase se se o o of MACE-free survi iva va val was observed with n n ncr r reasing FFR R R s s str rat tum um um ( ( ( Ta Ta Tabl bl ble e e 3 
The FFR gray zone
FFR has been initially validated against composite information from sequentially performed noninvasive tests. [20] [21] [22] It was shown that below the value of 0.75, epicardial stenoses were associated with 100% positive predictive value for stress-inducible myocardial ischemia, while an FFR value >0.80 has a negative predictive value of more than 95%. 20 The DEFER trial indicated that PCI of coronary stenoses with FFR values above 0.75 did not improve clinical outcome as compared to patients deferred to medical therapy. 1 In a minority of patients, an FFR value between 0.75 and 0.80 was found to be associated with typical exercise-induced angina and reversible flow maldistributions. 23 Therefore, in the era of drug-eluting stents, the threshold of 0.80 has been adopted in subsequent studies similar results have been obtained in multiple registries and real world practices accounting for more than 10000 patients. 24 FFR values between 0.75 and 0.80 have been referred to as the "FFR gray zone", alluding to some uncertainty regarding the degree of ischemia present related to the stenosis being interrogated.
FFR risk continuum
Our study provides novel data in a large dataset of carefully selected patients with single-vessel 25 The present data ex ex exte te tend nd nd t t thi hi his s s concept to lesions within the narrow range of 0.70 to 0.85. Even within this range of values, the owe we er r r th th the e e FF FF FFR R R va a alu lu lue, the higher the event rate. Th Th This is is finding is clinically y y r r relevant because almost h ha half f f of all FFR me m meas s sur ur urem em emen en ents ts s f f f l al all l l wi wi with th thin n thi hi his r r rang ge. . . M M Mor or oreo eo ove ve ver th th thes s se e le le es s sio ons ar ar are e e of of ofte te ten n n as as asso o oci ci ciat at ated ed ed wi wi with th th a atypica a al l l symp mp mptoms ms ms and d dub ub ubious us us res es esu ul u ts s s of f f non---inva va vas sive ve e t t tes es sti ti ing g g. On On One co oul ul u d d d argu gu gue e e th hat t t in h h hes es ese e e pa pa pati ti tien en ents ts ts l l lef ef eft t t un n unde de der r r me me medi di dica ca cal l l th th ther er erap ap apy, t t the he he a a awar ar aren en enes es ess s s by b by t t the he he p p pat at atie ie ient nt nt a a an n nd d d hi hi his s s ph ph phys s ysic ic icia ia ian n n of of of t t the he he significant dilution of the risk of coronary events as compared with patients within the gray zone.
Alternatively, we cannot exclude that this result has been due to the play of chance.
A similar "FFR risk continuum" was not observed in the group of patients who underwent revascularization. Stated another way, regardless of the actual FFR value, the risk of MACE remained similar after revascularization (supplemental table 3 ). This is in line with the results of the FAME 2 trial, in which patients with at least one hemodynamically significant stenosis and randomized to PCI had the same MACE rates as patients with no hemodynamically significant stenosis and treated with medical therapy. This suggests that one of the main determinants of outcome is the ischemic potential of the stenosis.
Medical Therapy versus Revascularization in the "Gray zone"
Confirming previous data, the present study indicates that below the threshold of 0.80 clinical outcomes tend to be better after revascularization with associated medical therapy than under medical therapy alone. 
Proximal versus distal location of the stenosis
In our study we included single vessel disease patients with single lesion mostly located in proximal coronary segments. We found that the interaction between FFR strata and MACE was significant in patients with stenoses located in proximal coronary segments, unlike in patients with stenoses located in distal coronary segments. This finding is not unexpected and underscores the clinical impact of hemodynamically significant proximal as compared with distal
Medical Therapy versus Revascularization in the "Gray zone"
Confirming previous data, the present study indicates that below the threshold of 0. 
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Limitations
The present study is retrospective, and revascularization was left to the operator's discretion.
Hence, a selection bias cannot be excluded. It is likely that lesion or patient's features not accounted for in the baseline characteristics have influenced the therapeutic decision. It should therefore be emphasized that, especially in the 'gray zone', the clinical context remains critically important. Along the same line, the small number of patients in the FFR strata 0.70-0.75 receiving medical therapy has to be acknowledged. This reflects the current attitude to revascularize hemodynamically significant lesions, especially in patients with isolated stenosis in a proximal segment. Third, the present conclusions were drawn in selected patients with a single lesion and might therefore not necessarily be extrapolated to more complex disease. Yet, this selection was done on purpose to minimize confounding factors and to render less elusive the mechanistic link between the stenosis and patient outcome. Fourth, our study included lesions mostly located on the LAD. Fifth, the overall rate of myocardial infarction (both peri-procedural or spontaneous) reported in our study is low. This might be due either to the definitions adopted or to under-reporting. Sixth, the lack of a prospective and independent Clinical Event Committee adjudication of the patients' events as well as of an independent core-lab evaluation of the coronary stenoses investigated represent limitations of our study.
Conclusion
Patients with an isolated stenosis located in a proximal coronary segment and FFR within the gray zone of 0.76-0.80 demonstrate a clinical outcome that is suboptimal when deferred to medical therapy alone. These data confirm the value of the 0.80 FFR threshold, and favor a revascularization strategy of coronary stenoses with FFR 0.80. a proximal segment. Third, the present conclusions were drawn in selected patient nt nts s s wi wi with th th a a a s s sin in ingl g g e esion and might therefore not necessarily be extrapolated to more complex disease. Yet, this ele ect ct ctio io ion n n wa wa was s s do o one ne ne on purpose to minimize conf f fou ou ound n n ing factors and to re re ender less elusive the m m mec c chanistic li link nk nk bet tw w ween en en t t the he he s s ste te ten no nosi si s s an an a d pa pa ati i ient ou u utcom om ome. e. 
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